HC Wainwright Has Lowered Expectations for GENFIT (NASDAQ:GNFT) Stock Price

Key Points

• HC Wainwright has **lowered its price objective** for GENFIT from **$9.00 to $7.00**, indicating a potential upside of **92.04%** from the last closing price.
• GENFIT's stock has seen a **12.2% decline** recently, with shares opening at **$3.65**, while having a 50-day moving average of **$4.01**.
• An institutional investor, **Millennium Management LLC**, has acquired a new stake in GENFIT, buying **166,375 shares** valued at approximately **$611,000** during the 4th quarter.

GENFIT (NASDAQ:GNFT - Get Free Report) had its price objective lowered by equities research analysts at HC Wainwright from $9.00 to $7.00 in a report released on Wednesday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. HC Wainwright's price objective suggests a potential upside of 92.04% from the company's previous close.

GENFIT Stock Down 12.2%

Shares of GENFIT stock opened at $3.65 on Wednesday. The stock has a 50-day moving average price of $4.01 and a 200 day moving average price of $3.90. The company has a debt-to-equity ratio of 0.08, a current ratio of 1.23 and a quick ratio of 1.23. GENFIT has a 1 year low of $2.55 and a 1 year high of $6.42.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in GENFIT stock. Millennium Management LLC bought a new position in GENFIT S.A. Unsponsored ADR (NASDAQ:GNFT - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 166,375 shares of the company's stock, valued at approximately $611,000. Millennium Management LLC owned about 0.33% of GENFIT at the end of the most recent reporting period. Hedge funds and other institutional investors own 2.24% of the company's stock.

About GENFIT

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.